Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 3, 1998, Pages

  Barnes, Thomas R E ^a   McPhillips, Mike A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Amisulpride; Clozapine; Extrapyramidal side effects; Olanzapine; Quetiapine; Risperidone; Sertindole; Tardive dyskinesia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

AKATHISIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN TISSUE; INCIDENCE; META ANALYSIS; MULTICENTER STUDY; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TARDIVE DYSKINESIA;

EID: 0031747423     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199803003-00009     Document Type: Review

References (99)

1. Addington DE, Toewes JA, Addington JM (1995). Risperidone and tardive dyskinesia. J Clin Psychiatry 56:484-485.
2. Addonzio G, Alexopoulos GS (1988). Drug-induced dystonia in young and elderly patients. Am J Psychiatry 145:869-871.
3. Adityanjee, Estrera AB (1996). Successful treatment of tardive dystonia with clozapine. Biol Psychiatry 39:1064-1065.
4. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernandez J, Gomez-Beneyto M, Schooler NR (1994). Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 151:1819-1821.
5. Anonymous (1988). Dystonia: underdiagnosed and undertreated? Drug Ther Bull 26:33-36.
6. Anonymous (1993). Risperidone and remoxipride for schizophrenia. Drug Ther Bull 31:101-102.
7. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group (1997). Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233-246.
8. Awad AG, Hogan TP (1994). Subjective response to neuroleptics and quality of life implications for treatment outcome. Acta Psychiatr Scand 89 (suppl 80):27-32.
9. Baldessarini RJ (1979). The pathophysiological basis of tardive dyskinesia. Trends Neurosci 2:133-135.
10. Barnes TRE (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
11. Barnes TRE (1990). Movement disorder associated with antipsychotic drugs: the tardive syndromes. Int Rev Psychiatry 2:355-366.
12. Barnes TRE (1992). Neuromuscular effects of neuroleptics: akathisia. In: Adverse effects of psychotropic drugs. Kane JM, Lieberman JA (editors). New York: Guilford Press. pp. 201-217.
13. Barnes TRE, Kane JM (1994). Assessment of movement disorders in psychosis. In: The assessment of psychoses: a practical handbook. London: Chapman and Hall Medical. pp. 200-210.
14. Barnes TRE, Kidger T (1978). Tardive dyskinesia and problems of assessment. In: Current themes in psychiatry. Vol 2. Gaind RN, Hudson BL (editors). London: Macmillan. pp. 145-162.
15. Barnes TRE, McPhillips MA (1996). Antipsychotic-induced extrapyramidal symptoms: role of anticholinergic drugs in treatment. CNS Drugs 6:315-330.
16. Barnes TRE, McPhillips MA, Hillier R, Puri BK, Joyce EM (1997). Compliance with maintenance medication in first-episode schizophrenia [abstract]. Schizophr Res 24:205.
17. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, and the Olanzapine HGAP Study Group (1996a). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159-167.
18. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, et al. (1996b). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
19. Bhavnani SM, Levin GM (1996). Antipsychotic agents: a survey of the prevalence, severity and burden of side effects. Int Clin Psychopharmacol 11:1-12.
20. Blin O, Azorin JM, Bouhours P (1996). Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 16:38-44.
21. Boumans CE, de Mooij KJ, Koch PAM, van't Hof MA, Zitman FG (1994). Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull 20:339-344.
22. Boyer P, Lecrubier Y, Peuch AJ, Dewailly J, Aubin F (1995). Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166:68-72.
23. Brecher M (1996). Long-term safety of risperidone [abstract P-15-1]. Eur Neuropsychopharmacol 6 (suppl 3):170.
24. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J (1982). Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32:1335-1346.
25. Burke RE (1992). Neuromuscular effects of neuroleptics: dystonia. In: Adverse effects of psychotropic drugs. Kane JM, Lieberman JA (editors). New York: Guilford Press. pp. 189-200.
26. Caine ED, Jolinsky RJ, Kartzinel R, Ebert MH (1979). The trial use of clozapine for abnormal involuntary movement disorder. Am J Psychiatry 136:317-320.
27. Carroll BJ, Curtiss CG, Kokmen E (1977). Paradoxical response to dopaminergic agonists in tardive dyskinesia. Am J Psychiatry 134:785-790.
28. Casey DE (1989). Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:47-53.
29. Casey DE (1995). Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 10 (suppl 3):105-114.
30. Casey DE (1996). Side effect profiles of new antipsychotic agents. J Clin Psychiatry 57:40-45.
31. Ceskova E, Svetska J (1996). Efficacy and tolerance of risperidone in various doses. Ceska Slovenska Psychiatrie 92:50-56.
32. Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J (1994). The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 55:142-145.
33. Chouinard G (1990). A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly-admitted schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 82 (suppl 358):111-119.
34. Chouinard G (1995). Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 15 (suppl 1):36-44.
35. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980). The extrapyramidal symptom rating scale. Can J Neurol Sci 7:233.
36. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. (1993). A Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40.
37. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G (1987). The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377-384.
38. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S (1992). Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 85:295-305.
39. Cohen BM, Keck PE, Satlin A, Cole JO (1991). Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 29:1215-1219.
40. Coukell AJ, Spencer CM, Benfield P (1996). Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6:237-256.
41. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams S (1996). Different side-effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 153:417-419.
42. Ereshefsky L, Watanabe MD, Tran-Johnson TK (1989). Clozapine: an atypical antipsychotic agent. Clin Pharmacol 8:691-709.
43. Factor SA, Friedman JH (1997). The emerging role of clozapine in the treatment of movement disorders. Mov Disord 12:483-496.
44. Fleischhacker WW, Meise U, Gunther V, Kurz M (1994). Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 89 (suppl 382):11-15.
45. Freeman HL (1997). Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia. Int Clin Psychopharmacol 12 (suppl 2):S11-S17.
46. Friedman JH (1994). Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases.Mov Disord 9:321-324.
47. Gerlach J, Peacock L (1995). Intolerance to neuroleptic drugs: the art of avoiding extrapyramidal syndromes. Eur Psychiatry 10 (suppl 1):27-33.
48. Goetz CG, Klawans HL (1981). Drug-induced extrapyramidal disorders: a neuropsychiatric interface. J Clin Psychopharmacol 1:297-303.
49. Goff DC, Shader RJ (1995). Non-neurological side effects of antipsychotic agents. In: Schizophrenia. Hirsch SR, Weinberger DR (editors). Oxford: Blackwell Science. pp. 566-584.
50. Halstead SM, Barnes TRE, Speller JC (1994). Akathisia: prevalence and associated dysphoria in an inpatient population with chronic schizophrenia. Br J Psychiatry 164:177-183.
51. Hummer M, Fleischhacker WW (1996). Compliance and outcome in patients treated with antipsychotics. CNS Drugs 5 (suppl 1):13-20.
52. Jankovic J, Schwartz KS, Donovan DT (1990). Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 53:633-639.
53. Kane JM (1994). Risperidone [editorial]. Am J Psychiatry 151: 802-803.
54. Kane JM, Lieberman J (1992). Tardive dyskinesia. In: Adverse effects of psychotropic drugs. Kane JM, Lieberman JA (editors). New York: Guilford Press. pp. 235-245.
55. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
56. Kane JM, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM, et al. (1992). Tardive dyskinesia: a Task Force report of the American Psychiatric Association. Washington (DC): American Psychiatric Association.
57. Keks NA (1996). Minimizing the non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand 94:18-24.
58. Kerwin RW (1994). The new atypical antipsychotics: a lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry 164:141-148.
59. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K (1995). Randomised, double-blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 15 (suppl 1):45-51.
60. Koshino Y, Madokoro S, Ito T, Horie T, Mukai M, Isaki K (1992). A survey of tardive dyskinesia in psychiatric inpatients in Japan. Clin Neuropsychopharmacol 15:34-43.
61. Kurz M, Hummer M, Oberbauer H, Fleischhacker WW (1995). Extrapyramidal side-effects of clozapine and haloperidol. Psychopharmacology 118:52-56.
62. Lamberti JS, Bellnier T (1993). Clozapine and tardive dyskinesia. J Nerv Ment Dis 181:137-138.
63. Lees AJ, Turjanski N, Rivest J, Whurr R, Lorch M, Brookes G (1992). Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin. J Neurol 239:1-4.
64. Lewander T, Westerbergh S-E, Morrison D (1990). Clinical profile of remoxipride: a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand 82:92-98.
65. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane JM (1991). The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503-510.
66. Linazasoro G, Marti-Masso JF, Suarez JA (1993). Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 8:1717-1714.
67. Loo H, Poirier-Littre M-F, Theron M, Rein W, Fleurot O (1997). Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18-22.
68. McCreadie RG (1992).The Nithsdale schizophrenia surveys: an overview. Soc Psychiatry Psychiatr Epidemiol 27:40-45.
69. Marder SR, Meibach RC (1994). Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
70. Marsden CD, Quinn NP (1990). The dystonias. BMJ 300:139-144.
71. Möller H-J (1996). Extrapyramidal side-effects of neuroleptic medication: focus on risperidone. In: Serotonin in antipsychotic treatment: mechanisms and clinical practice. Kane JM, Möller H-J, Awouters F (editors). New York: Marcel Dekker. pp. 345-356.
72. Mortimer A, Barnes TRE (1996). The treatment of schizophrenia: comparative studies with placebo, haloperidol and risperidone. In: Serotonergic mechanisms in antipsychotic treatment. Kane JM, Möller H-J, Awouters F (editors). New York: Marcel Dekker. pp. 311-330.
73. Owens DGC (1996). Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs 51:895-930.
74. Pandurangi AK, Aderibigbe YA (1995). Tardive dyskinesia in non-Western countries: a review. Euro Arch Psychiatry Clin Neurosci 246:47-52.
75. Peuskens J (1995). Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726.
76. Peuskens J, Link CGG (1997). A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96:265-273.
77. Pfeiffer C, Wagner ML (1994). Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm 51:3047-3053.
78. Raja M (1995). Tardive dystonia: prevalence, risk factors and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients. Eur Arch Psychiatry Clin Neurosci 245:145-151.
79. Richardson MA, Haugland G, Craig TJ (1991). Neuroleptic use, parkinsonian symptoms, tardive dyskinesia and associated factors in children and adolescent psychiatric patients. Am J Psychiatry 148:1322-1328.
80. Rupniak NMJ, Jenner P, Marsden CD (1986). Acute dystonia induced by neuroleptic drugs. Psychopharmacology 88:403-419.
81. Safferman AZ, Lieberman JA, Pollack S, Kane JM (1993). Akathisia and clozapine treatment. J Clin Psychopharmacol 13: 286-287.
82. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 212 (suppl 44):11-19.
83. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, and the Seroquel Study Group (1997). Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 54:549-557.
84. Song F (1997) Risperidone in the treatment of schizophrenia: a meta-analysis of randomized, controlled trials. J Psychopharmacol 11:65-71.
85. Speller JC, Barnes TRE, Curson DA, Pantelis C, Alberts JL (1997). A one-year, low-dose neuroleptic study in chronic schizophrenic inpatients characterised by persistent negative symptoms: amisulpride versus haloperidol. Br J Psychiatry 171:564-568.
86. Swett C (1975). Drug-induced dystonia. Am J Psychiatry 132: 532-534.
87. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB (1997). Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12 (suppl 1):S29-S35.
88. Tollefson GD, Tran PV, Hamilton S, Kuntz A (1997). Olanzapine versus risperidone in the treatment of psychosis: preliminary report [abstract]. Schizophr Res 24:191-192.
89. Trugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF (1994). Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord 9:441-446.
90. Umbricht D, Kane JM (1996a). Understanding the relationship between extrapyramidal side-effects and tardive dyskinesia. In: Serotonergic mechanisms in antipsychotic treatment. Kane JM, Möller H-J, Awouters F (editors). New York: Marcel Dekker. pp. 221-251.
91. Umbricht D, Kane JM (1996b). Medical complications of new antipsychotic drugs. Schizophr Bull 22:475-483.
92. Van Putten T, May PRA, Marder SR, Wittmann LA (1981). Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38:187-190.
93. Whitworth AB, Fleischhacker WW (1995). Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 9 (suppl 5):21-27.
94. Wirshing WC, Phelan CK, Van Putten T, Marder SR, Engel J (1990). Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia. J Clin Psychopharmacol 10:371-373.
95. Woerner MG, Sheitman BB, Lieberman JA, Kane JM (1996). Tardive dyskinesia induced by risperidone? Am J Psychiatry 153:843.
96. Wojcik JD, Falk WE, Fink JS, Cole JO, Gelenberg AJ (1991).A review of 32 cases of tardive dystonia. Am J Psychiatry 148:1055-1059.
97. Yassa R, Nair V, Dimitry R (1986). Prevalence of tardive dystonia. Acta Psychiatr Scand 73:629-633.
98. Youssef HA, Waddington JL (1987). Morbidity and mortality in tardive dyskinesia in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 75:74-77.
99. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154:782-791.